NEW YORK CITY, NY / ACCESS Newswire / April 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the ...

View Our Latest Stock Report on Akero Therapeutics Akero Therapeutics Stock Down 2.0 % The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. The ...

Akero Therapeutics' EFX showed remarkable efficacy in reversing cirrhosis in the long-term SYMMETRY trial, a significant milestone in MASH treatment. EFX demonstrated consistent efficacy across ...

Akero Therapeutics, Inc. has a 52-week low of $17.86 and a 52-week high of $58.40. The firm has a market capitalization of $2.92 billion, a price-to-earnings ratio of -9.79 and a beta of -0.18.

NEW YORK CITY, NY / ACCESS Newswire / April 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Akero Therapeutics Inc (Symbol: AKRO) entered into oversold territory, hitting an RSI ...

NEW YORK CITY, NY / ACCESS Newswire / April 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the ...

Uncertainties surrounding the U.S. pharmaceutical sector and the turbulent development in global stock markets have led to ...

If you own Akero Therapeutics, Inc. ("Akero") (NASDAQ:AKRO), please contact Fletcher Moore by email at [email protected] or (212) 709-8245. You may be able to seek monetary damages ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

If you own Akero Therapeutics, Inc. ("Akero") (NASDAQ:AKRO ), please contact Fletcher Moore by email at ... or (212) 709-8245. You may be able to seek monetary damages, corporate governance ...

A drug developed by US biotech Akero Therapeutics has hit the mark in a phase 2b trial in non-alcoholic steatohepatitis (NASH) – catapulting it to the forefront of efforts to find effective ...